BioSpace News Archive

The Somatic Experiencing® Trauma Institute announced it has developed a comprehensive set of tools to help people self-regulate and stabilize during times of crisis and stress.

Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced results from in vitro studies evaluating the use of PTI-1

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced the appointment of Gilbert H. Kliman, M.D., Managing Partner, InterWest Partners and Thomas G. Frinzi, former Worldwide President, Surgical, Johnson & Johnson Vision, to its Board of Directors, effective June 1, 2020.

The American College of Emergency Physicians denounces racism and all senseless acts of violence.

The Oncology Nursing Foundation has committed $420,000 over the next two years to support three major research grants that will be led by oncology nurse scientists.

South Carolina-based Hoowaki LLC has developed an innovative one-piece injection molded design for a COVID-19 swab to help close the gap in U.S. and global COVID-19 testing supplies.

AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC).

As the number of patients who require care for COVID-19 across the state of Michigan decreases and restrictions put in place by the Governor are lifted, Karmanos Cancer Institute continues to offer all cancer care services.

People with diabetes are three times as likely to need hospitalization if infected with COVID-19

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported completion of enrollment and randomization in its EMERGE pivotal Phase 3 efficacy trial of STS101 nasal powder) for the acute treatment of migraine.